home / stock / mrk / mrk articles

MRK Articles, Merck & Company Inc. - From 06/18/24

Stock Information
Company Name: Merck & Company Inc.
Stock Symbol: MRK
Market: NYSE
Website: merck.com
Menu
MRK MRK Quote MRK Short MRK News MRK Articles MRK Message Board
Get MRK Alerts

News, Short Squeeze, Breakout and More Instantly...
Covid-19 Pharma Stars Continue Their Quest To Set New Standards In Cancer Treatment | Benzinga

AstraZeneca PLC (NASDAQ: AZN) kicked off the week by receiving approval from the U.S. Food and Drug Administration for its ...
FDA Approves Merck's Pneumococcal Vaccine As First Shot Designed For Adults | Benzinga

Monday, the FDA approved Merck & Co Inc’s (NYSE: MRK) Capvaxive (Pneumococcal 21-valent Conjugate Vaccine) to protect against 2...

Nike, Merck, General Motors, And More: CNBC's 'Final Trades' | Benzinga

On CNBC's “Halftime Report Final Trades,” Liz Young of SoFi named The Energy Select Sector SPDR Fund (NYSE:XLE) as her final trade...

Promising Trial Results Show New Standards In Cancer Treatment And Diagnostics Are On The Horizon | Benzinga

On Friday, Pfizer Inc (NYSE: PFE) revealed its drug for an advanced form of lung cancer showed promising long-term results in a late-stage tri...
Comparative Study: Merck & Co And Industry Competitors In Pharmaceuticals Industry | Benzinga

In the fast-paced and highly competitive business world of today, conducting thorough company analysis is essential for investors and industry obse...

Moderna, Merck Reveal Three Year Data For Individualized Cancer Therapy In High-Risk Melanoma Patients | Benzinga

Monday, Moderna Inc (NASDAQ:MRNA) and Merck & Co Inc (NYSE:MRK) announced the first presentation of results from a planned analysis f...

Summit Therapeutics' Lung Cancer Therapy Ivonescimab Shows Improved Progression-Free Survival Versus Merck's Multi-Billion Keytruda In China Study | Benzinga

On Friday, Summit Therapeutics Inc (NASDAQ:SMMT) shares are trading lower after the company’s stock closed 272.1% higher at $10.92 on Thursda...
Merck Reportedly Nearing $1.3B Acquisition Of EyeBio To Expand Eye-Care Market Presence | Benzinga

Merck & Co., Inc. (NYSE:MRK) is reportedly on the verge of acquiring EyeBio, an eye drug company, for a sum of $1.3 billion. This acquisition i...

Merck's Multi-Billion Cancer Drug Keytruda Aces Late-Stage Breast Cancer Study (UPDATED) | Benzinga

Editor’s Note: The title of the story is updated to correct the reference to ‘Breast’ cancer instead of ‘Lung’ cancer...

Merck's Multi-Billion Cancer Drug Keytruda Aces Late-Stage Lung Cancer Study | Benzinga

Tuesday, Merck & Co Inc (NYSE:MRK) released topline data from hase 3 KEYNOTE-522 trial of Keytruda in high-risk early-stage ...
Previous 10 Next 10